Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Christophe Tournigand

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6232-4815; OpenAlex author ID A5020893157. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  2. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  3. No changes in clinical presentation, treatment strategies and survival of pancreatic cancer cases during the SARS-COV-2 outbreak: A retrospective multicenter c… Last author DOI 10.1002/ijc.34675↗
  4. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  5. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Co-author DOI 10.6004/jnccn.2023.7065↗
  6. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Co-author DOI 10.3390/cancers14174265↗
  7. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Co-author DOI 10.3390/cancers14246160↗
  8. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  9. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  10. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leu… Co-author DOI 10.1002/cam4.2311↗
  11. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR)… Co-author DOI 10.1016/s2468-1253(17)30046-8↗
  12. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  13. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancr… Last author DOI 10.1097/md.0000000000004006↗
  14. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.pharmthera.2015.08.006↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 8 shared papers, 2015–2026 · strength 0.88
  2. Jean‐Baptiste Bachet · 7 shared papers, 2017–2026 · strength 0.81
  3. Christophe Louvet · 6 shared papers, 2017–2026 · strength 0.57
  4. Jerome F. Cros · 5 shared papers, 2015–2026 · strength 0.56
  5. Cindy Neuzillet · 5 shared papers, 2015–2026 · strength 0.54
  6. Olivier Bouché · 5 shared papers, 2017–2025 · strength 0.53
  7. Isabelle Trouilloud · 3 shared papers, 2023–2026 · strength 0.51
  8. Thierry André · 4 shared papers, 2017–2026 · strength 0.44
  9. Christelle de la Fouchardière · 3 shared papers, 2020–2026 · strength 0.39
  10. Emmanuelle Kempf · 3 shared papers, 2016–2023 · strength 0.35
  11. Benoı̂t Rousseau · 3 shared papers, 2016–2026 · strength 0.34
  12. Fabienne Portales · 3 shared papers, 2020–2025 · strength 0.33
  13. David Tougeron · 3 shared papers, 2020–2025 · strength 0.33
  14. Déwi Vernerey · 2 shared papers, 2017–2026 · strength 0.28
  15. Anaïs Debesset · 2 shared papers, 2022 · strength 0.23
  16. Rémy Nicolle · 2 shared papers, 2022 · strength 0.23
  17. Matteo Ponzo · 2 shared papers, 2022 · strength 0.23
  18. Corinne Bousquet · 2 shared papers, 2022 · strength 0.23
  19. Mounira Chalabi‐Dchar · 2 shared papers, 2022 · strength 0.23
  20. José Laurent Cohen · 2 shared papers, 2022 · strength 0.23
  21. Fabio Raineri · 2 shared papers, 2022 · strength 0.23
  22. Philippe Bouvet · 2 shared papers, 2022 · strength 0.23
  23. Ilaria Cascone · 2 shared papers, 2022 · strength 0.23
  24. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  25. Marc Hilmi · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.